"Bridging" therapy with low molecular weight heparin in pregnant patients and patients with mechanical prosthetic heart valves

Journal of Thrombosis and Thrombolysis

Volumn 16, Issue 1-2, 2003, Pages 79-82

  Groce III, James B ^a,b  

^a Campbell University   (United States)

^b MOSES H CONE MEMORIAL HOSPITAL   (United States)

Author keywords

Anticoagulation; Low molecular weight heparin; Mechanical heart valve; Pregnancy

Indexed keywords

DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INFORMATION; DRUG PACKAGING; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; HEART VALVE PROSTHESIS; HIGH RISK POPULATION; HUMAN; ISCHEMIA; PREGNANCY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SKIN BRUISING; STROKE; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS; ENOXAPARIN; FEMALE; HEART VALVE PROSTHESIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PRACTICE GUIDELINES; PREGNANCY;

EID: 1842741383     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:THRO.0000014599.17795.39     Document Type: Article

References (24)

1. Lovenox Injection (package insert). Aventis Pharmaceuticals, 2002.
2. Lovenox Injection (package insert). Available at www. aventis-us.com/PIs/lovenox. Accessed July 30, 2003. Aventis Pharmaceuticals, 2003.
3. Data on File. Aventis Pharmaceuticals, 2002.
4. Laurent P, Dussarat GV, Bonal J, et al. Low molecular weight heparins: A guide to their optimum use in pregnancy. Drugs 2002;62:463-477.
5. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220s-227s.
6. Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000;1010:1083-1086.
7. Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin (abstract). Thromb Haemost 2001; Abstract P2323.
8. Berdague P, Boneu B, Soula P, et al. Usefulness of low-molecular weight heparins during post-operative period in mitral mechanical valve replacement: Clinical ischaemic and haemorrhagic complications in 110 cases [abstract]. Eur Hear J 1999;19(Abstrt. Suppl):534. Abstract P2965.
9. Ferreira IJ, Dos L, Tornos MP, et al. Is low-molecular weight heparin a safe alternative to unfractionated heparin in patients with mechanical heart valves who must interrupt antithrombotic therapy. Eur Heart J 2000; 21(Abstract Suppl 310). Abstract P1666.
10. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003;89:527-530.
11. Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynecol 2000;107:1116-1121.
12. Dulitzki M, Pauzner R, Langevitz P, et al. Low molecular weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstet Gynecol 1996;87:380-383.
13. Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997;176:1062-1068.
14. Bonnar J, Norris LA, Greene R. Low molecular weight heparin for thromboprophylaxis during caesarean section. Thromb Res 1999;96:317-322.
15. Borel-Derlon A, Borg JY, Boudignat O. Assessment of a low molecular weight heparin (enoxaparin) safety during pregnancy: A retrospective study of 624 pregnancies (Abstract). International Society of Thrombosis and Hemostasis 1999:1550.
16. Position statement on LMWH posted on http://www.smfm. org/. Accessed July 30, 2003.
17. Casele H, Laifer A, Woelkers DA, et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999;181:1113-1117.
18. Ellison J, Thomson AJ, Walker ID, et al. Use of enoxaparin in a pregnant woman with a mechanical heart valve prosthesis. Br J Obstet Gynecol 2001;108:757-759.
19. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119:122s-131s.
20. Sadler L, McCowan L, White H, Stewart A, Bracken M, North R. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. Bog 2000;107:245-253.
21. Meschengieser SS, Fondevila CG. Anticoagulation in pregnant women with mechanical heart valve prostheses. Heart 1999;82:23-26.
22. Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. Journal of the American College of Cardiology 1996;27:1698-1703.
23. Watson WJ, Freeman J, O'Brien C, Benson M. Embolic stroke in a pregnant patient with a mechanical heart valve on optimal heparin therapy. American Journal of Perinatology 1996;13:371-372.
24. Salazar E, Zajarias A, Guiterrez N. The problem of cardiac valve prostheses, anticoagulants and pregnancy. Circulation 1997;70(Suppl 1):169-177.